Bristol Glucophage Strategy Lifts Stock As Sector Wilts From Medicare Redux
Executive Summary
Bristol-Myers Squibb's diabetes portfolio was a sweetener for the Street as the stock turned in one of the few positive showings among big pharma companies during a quarter marked by increasing political rhetoric over a Medicare drug benefit.
You may also be interested in...
Bergen Pursues Legislative, Managerial Remedies for PharMerica
Reimbursement pressure on Bergen Brunswig's PharMerica long-term care pharmacy business is prompting the parent company to lobby for changes to Medicare's Prospective Payment System.
Bergen Pursues Legislative, Managerial Remedies for PharMerica
Reimbursement pressure on Bergen Brunswig's PharMerica long-term care pharmacy business is prompting the parent company to lobby for changes to Medicare's Prospective Payment System.
Bristol's Orzel Will Be Reviewed By FDA Oncologics Cmte. In September
Bristol-Myers Squibb's colorectal cancer therapy Orzel (UFT/leucovorin) is slated for review in September by FDA's Oncologic Drugs Advisory Committee, Bristol CFO Michael Mee said during a July 21 teleconference discussing the firm's second quarter results.